sofinnova
(2)
Perry Nisen
Perry Nisen is a physician-scientist and CEO of Quanta Therapeutics, a South San Francisco biotech building next-generation oral KRAS inhibitors for RAS-driven cancers. A former pediatric oncologist turned pharma executive, he ran the GSK oncology portfolio later acquired by Novartis for over $16 billion, led the Sanford Burnham Prebys research institute, and serves on Teva's board. He now chases the 'undruggable' mutations that drive a quarter of all human cancers.
Eric Delbridge
Eric Delbridge, MD is a General Partner at Sofinnova Investments in Menlo Park, California, where he architects the firm's BioEquities strategy - a $1.5B public equity fund focused on global therapeutics companies. An unusual combination of physician, Wharton MBA (Palmer Scholar), and Yale Classics graduate, Delbridge brings over a decade of hedge fund investing experience from Balyasny Asset Management and Spring Point Capital, plus prior investment banking work at Lazard and Credit Suisse. He joined Sofinnova in 2016 and was elevated to General Partner in 2019, helping steward a firm with $3.7B under management, 118 companies funded, 55 IPOs, and 30 acquisitions.